Hannah Yang

发表

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

W. Lee, Chan Kim, Hannah Yang, 2020, Experimental & Molecular Medicine.

Novel Glycosylated VEGF Decoy Receptor Fusion Protein, VEGF-Grab, Efficiently Suppresses Tumor Angiogenesis and Progression

S. C. Kim, Ho Min Kim, G. Koh, 2014, Molecular Cancer Therapeutics.

Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer

Yu Seong Lee, W. Lee, Chan Kim, 2020, Journal for ImmunoTherapy of Cancer.

Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade

Joo Hoon Kim, Eun Chun Han, Jiwon Choi, 2018, Clinical Cancer Research.

Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway

Jeong Hun Kim, J. Cheon, Hyun-jin Yang, 2021, Oncoimmunology.

VEGF-Grab Enhances the Efficacy of Radiation Therapy by Blocking VEGF-A and Treatment-Induced PlGF.

E. Choi, G. Koh, Intae Park, 2018, International journal of radiation oncology, biology, physics.

Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non–Small Cell Lung Cancer

Deokhoon Kim, E. Choi, Sang-We Kim, 2021, Cancer research and treatment.

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade

Jeong Hun Kim, Jin Hyoung Kim, W. Lee, 2022, Journal for ImmunoTherapy of Cancer.

STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer

Yu Seong Lee, Jeong Hun Kim, J. Cheon, 2021, Journal for ImmunoTherapy of Cancer.

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma

J. Cheon, H. Lim, W. Lee, 2022, JAMA oncology.

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma

J. Cheon, S. Rha, W. Lee, 2023, JHEP reports : innovation in hepatology.

HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.

Sang-We Kim, Dae-Ho Lee, G. Koh, 2017, Cancer letters.

Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis

Joo Hoon Kim, S. Rha, Intae Park, 2016, Journal of Cancer.

SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo

Yong Xu, Yang Yu, Xin Chen, 2012, Molecular Cancer Therapeutics.

Preclinical Development SKLB 1206 , a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T 790 M Mutants , ErbB 2 , ErbB 4 , and VEGFR 2 , Displays Potent Antitumor Activity Both In Vitro and In Vivo

Shan Feng, Shi-Dong Luo, You-Li Pan, 2012 .

The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.

Ky-Youb Nam, Sang-We Kim, Dae-Ho Lee, 2016, Cancer letters.

Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway

So Jung Kong, Beodeul Kang, Jongsun Jung, 2021, Oncoimmunology.

Multiple primary melanoma revisited

D. Elder, D. Guerry, M. Synnestvedt, 2002, Cancer.

STING signaling is a potential immunotherapeutic target in colorectal cancer

Yu Seong Lee, Jung Hyun Noh, Seung Jun Lee, 2019, Journal of Cancer.

High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer

Su-Jin Shin, J. Cheon, H. Park, 2021, Journal for ImmunoTherapy of Cancer.

The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.

Deokhoon Kim, Sang-We Kim, Dae-Ho Lee, 2017, Cancer letters.

STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.

Joo Hoon Kim, W. Lee, Gwangil Kim, 2019, The Journal of clinical investigation.

Abstract 2092: Artificial intelligence technology enables a rational development of a potent immunotherapeutic agent

Won Suk Lee, Jeong Hun Kim, Hye Jin Lee, 2020 .

Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy

D. Han, Dong‐Hyun Kim, Dasom Yang, 2020, Cancers.

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma

J. Cheon, W. Lee, Seul-Gi Kim, 2022, Cancers.

High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma

J. Cheon, W. Lee, Hannah Yang, 2023, Journal of Cancer.

Abstract 1914: Orally available oncolytic reovirus, RC402, effectively promotes anti-cancer immunity and synergizes with immune checkpoint blockade in colon cancer

Yu Seong Lee, Jeong Hun Kim, Y. Lee, 2021, Immunology.

Chronic Shedding of a SARS-CoV-2 Alpha Variant Lineage Q.3/Q.4 in Wastewater

Maggie R. Williams, E. Alm, Hannah Yang, 2023, medRxiv.

Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.

W. Lee, W. Park, Hannah Yang, 2023, Small.

PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis

W. Lee, Hannah Yang, H. Chon, 2023, Oncoimmunology.